SG162616A1 - Combinations comprising epothilones and pharmaceutical uses thereof - Google Patents
Combinations comprising epothilones and pharmaceutical uses thereofInfo
- Publication number
- SG162616A1 SG162616A1 SG200608597-1A SG2006085971A SG162616A1 SG 162616 A1 SG162616 A1 SG 162616A1 SG 2006085971 A SG2006085971 A SG 2006085971A SG 162616 A1 SG162616 A1 SG 162616A1
- Authority
- SG
- Singapore
- Prior art keywords
- combination
- inhibitors
- treatment
- simultaneous
- separate
- Prior art date
Links
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 abstract 1
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 abstract 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 abstract 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 abstract 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229940046844 aromatase inhibitors Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229960001442 gonadorelin Drugs 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003881 protein kinase C inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38702502P | 2002-06-10 | 2002-06-10 | |
| US40623902P | 2002-08-27 | 2002-08-27 | |
| US40623802P | 2002-08-27 | 2002-08-27 | |
| US43867703P | 2003-01-08 | 2003-01-08 | |
| US43867603P | 2003-01-08 | 2003-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG162616A1 true SG162616A1 (en) | 2010-07-29 |
Family
ID=29741146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200608597-1A SG162616A1 (en) | 2002-06-10 | 2003-06-06 | Combinations comprising epothilones and pharmaceutical uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20050271669A1 (enExample) |
| EP (2) | EP2179745A1 (enExample) |
| JP (1) | JP2005535608A (enExample) |
| CN (2) | CN1658904A (enExample) |
| AT (1) | ATE476995T1 (enExample) |
| AU (1) | AU2003242646A1 (enExample) |
| BR (1) | BR0311714A (enExample) |
| CA (1) | CA2487147A1 (enExample) |
| DE (1) | DE60333754D1 (enExample) |
| IL (1) | IL165180A0 (enExample) |
| MX (1) | MXPA04012444A (enExample) |
| NO (1) | NO20050096L (enExample) |
| PL (1) | PL372070A1 (enExample) |
| SG (1) | SG162616A1 (enExample) |
| WO (1) | WO2003103712A1 (enExample) |
| ZA (1) | ZA200409137B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
| EP1824831A2 (en) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2008540574A (ja) | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| CN101263121A (zh) | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
| WO2008058287A1 (en) * | 2006-11-10 | 2008-05-15 | Syndax Pharmaceuticals, Inc. | COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2009015237A1 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| US20100298270A1 (en) * | 2007-07-23 | 2010-11-25 | Syndax Pharmaceuticals, Inc. | Novel Compounds and Methods of Using Them |
| WO2009058895A1 (en) * | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
| US20090131367A1 (en) * | 2007-11-19 | 2009-05-21 | The Regents Of The University Of Colorado | Combinations of HDAC Inhibitors and Proteasome Inhibitors |
| US20110182888A1 (en) * | 2008-04-08 | 2011-07-28 | Peter Ordentlich | Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
| WO2011146638A1 (en) | 2010-05-18 | 2011-11-24 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| WO2018081556A1 (en) * | 2016-10-28 | 2018-05-03 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999039694A2 (en) * | 1998-02-05 | 1999-08-12 | Novartis Ag | Compositions containing organic compounds |
| WO2000000485A1 (de) * | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
| WO2000049019A2 (de) * | 1999-02-18 | 2000-08-24 | Schering Aktiengesellschaft | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| US20020002162A1 (en) * | 2000-03-27 | 2002-01-03 | Lee Francis Y. | Synergistic methods and compositions for treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| US6242469B1 (en) * | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| ATE307123T1 (de) * | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| WO2000047584A2 (de) * | 1999-02-11 | 2000-08-17 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU2001243372A1 (en) * | 2000-03-01 | 2001-09-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| DE10020517A1 (de) * | 2000-04-19 | 2001-10-25 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| DE10020899A1 (de) * | 2000-04-20 | 2001-10-25 | Schering Ag | 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| CA2440555A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
-
2003
- 2003-06-06 AU AU2003242646A patent/AU2003242646A1/en not_active Abandoned
- 2003-06-06 EP EP20090178302 patent/EP2179745A1/en not_active Withdrawn
- 2003-06-06 MX MXPA04012444A patent/MXPA04012444A/es active IP Right Grant
- 2003-06-06 DE DE60333754T patent/DE60333754D1/de not_active Expired - Lifetime
- 2003-06-06 BR BR0311714-6A patent/BR0311714A/pt not_active IP Right Cessation
- 2003-06-06 JP JP2004510831A patent/JP2005535608A/ja active Pending
- 2003-06-06 US US10/517,074 patent/US20050271669A1/en not_active Abandoned
- 2003-06-06 EP EP03757040A patent/EP1515750B1/en not_active Expired - Lifetime
- 2003-06-06 AT AT03757040T patent/ATE476995T1/de not_active IP Right Cessation
- 2003-06-06 CA CA002487147A patent/CA2487147A1/en not_active Abandoned
- 2003-06-06 WO PCT/EP2003/005988 patent/WO2003103712A1/en not_active Ceased
- 2003-06-06 CN CN038134489A patent/CN1658904A/zh active Pending
- 2003-06-06 SG SG200608597-1A patent/SG162616A1/en unknown
- 2003-06-06 PL PL03372070A patent/PL372070A1/xx not_active Application Discontinuation
- 2003-06-06 CN CN201010166742A patent/CN101816792A/zh active Pending
-
2004
- 2004-11-11 IL IL16518004A patent/IL165180A0/xx unknown
- 2004-11-11 ZA ZA2004/09137A patent/ZA200409137B/en unknown
-
2005
- 2005-01-07 NO NO20050096A patent/NO20050096L/no unknown
-
2010
- 2010-10-20 US US12/908,533 patent/US20110033458A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999039694A2 (en) * | 1998-02-05 | 1999-08-12 | Novartis Ag | Compositions containing organic compounds |
| WO2000000485A1 (de) * | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
| WO2000049019A2 (de) * | 1999-02-18 | 2000-08-24 | Schering Aktiengesellschaft | Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung |
| US20020002162A1 (en) * | 2000-03-27 | 2002-01-03 | Lee Francis Y. | Synergistic methods and compositions for treating cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| PL372070A1 (en) | 2005-07-11 |
| CN101816792A (zh) | 2010-09-01 |
| ATE476995T1 (de) | 2010-08-15 |
| NO20050096L (no) | 2005-02-04 |
| EP1515750B1 (en) | 2010-08-11 |
| WO2003103712A1 (en) | 2003-12-18 |
| CN1658904A (zh) | 2005-08-24 |
| EP1515750A1 (en) | 2005-03-23 |
| JP2005535608A (ja) | 2005-11-24 |
| AU2003242646A1 (en) | 2003-12-22 |
| US20050271669A1 (en) | 2005-12-08 |
| ZA200409137B (en) | 2005-08-31 |
| EP2179745A1 (en) | 2010-04-28 |
| US20110033458A1 (en) | 2011-02-10 |
| HK1075208A1 (en) | 2005-12-09 |
| DE60333754D1 (de) | 2010-09-23 |
| CA2487147A1 (en) | 2003-12-18 |
| MXPA04012444A (es) | 2005-04-19 |
| BR0311714A (pt) | 2005-03-01 |
| IL165180A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG162616A1 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| WO2006059234A3 (en) | Bicyclic amides as kinase inhibitors | |
| MXPA05003253A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos. | |
| EA200501586A1 (ru) | Фармацевтические продукты | |
| IL284930A (en) | History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases | |
| WO2005014572A8 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
| NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
| WO2004091591A3 (fr) | Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives | |
| MXPA04000567A (es) | COMBINACIONES QUE COMPRENDEN EPOTILONAS Y SUS USOS FARMACeUTICOS. | |
| SE0002729D0 (sv) | Novel compound form | |
| WO2005074989A3 (en) | Combination of a dna topoisomerase inhibitor and an iap inhibitor | |
| TW200637542A (en) | Lipase inhibitor, preventing and treating agent of skin disease | |
| TW200628468A (en) | Bicyclononene derivatives | |
| TW200634002A (en) | Chemical compounds | |
| ECSP045479A (es) | Combinaciones que comprenden epotilonas y sus usos farmaceuticos | |
| MXPA04003124A (es) | Composicion farmaceutica que comprende un agonista de adenosina a1/a2 y un inhibidor de intercambiadores sodio-hidrogeno. | |
| RU2004139234A (ru) | Комбинации, включающие эпотилоны, и их фармацевтическое применение | |
| BR0312283A (pt) | Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf | |
| PL375503A1 (en) | Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor | |
| WO2004105738A3 (en) | Use of tetrahydropyridine derivatives | |
| EA200501366A1 (ru) | Лекарственное средство |